Statins suppress glucose-induced plasminogen activator inhibitor-1 expression by regulating RhoA and nuclear factor-kB activities in cardiac microvascular endothelial cells

Experimental Biology and Medicine

Volumn 238, Issue 1, 2013, Pages 37-46

  Ni, Xiao Qing ^a,b   Zhu, Jian Hua ^b   Yao, Ning Hua ^b   Qian, Juan ^b   Yang, Xiang Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Endothelial cells; Metabolic syndrome; NF kB; PAI 1; Rho Rho kinase; Statin

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; ATORVASTATIN; EXOENZYME C3; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GLUCOSE; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MEVALONIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; MALE; METABOLIC SYNDROME X; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NF-KAPPA B; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN;

RATTUS;

EID: 84875626624     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.012127     Document Type: Article

References (40)

1. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003;108:1655-61.
2. Krysiak R, Gdula-Dymek A, Okopień B. Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacol Rep 2010;62:1090-8.
3. Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008;100:969-75.
4. Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, Fujii S, Tsutsui H, Tamaki N. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J 2007;71:348-53.
5. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-80.
6. Tetik S, Ak K, Sahin Y, Gulsoy O, Isbir S, Arsan S, Yardimci T. Postoperative statin therapy attenuates the intensity of systemic inflammation and increases fibrinolysis after coronary artery bypass grafting. Clin Appl Thromb Hemost 2011;17:526-31.
7. Walter T, Szabo S, Suselbeck T, Borggrefe M, Lang S, Swoboda S, Hoffmeister HM, Dempfle CE. Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. Clin Drug Invest 2010;30:453-60.
8. Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34.
9. Dong M, Yan BP, Yu CM. Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. Cardiovasc Hematol Agents Med Chem 2009;7:322-30.
10. Zhou H, Li YJ. RhoA/Rho kinase: a novel therapeutic target in diabetic complications. Chin Med J 2010;123:2461-6.
11. Ishibashi T, Nagata K, Ohkawara H, Sakamoto T, Yokoyama K, Shindo J, Sugimoto K, Sakurada S, Takuwa Y, Teramoto T, Maruyama Y. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta 2002;1590:123-30.
12. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006;17:754-64.
13. Dunoyer-Geindre S, Fish RJ, Kruithof EK. Regulation of the endothelial plasminogen activator system by fluvastatin. Role of Rho family proteins, actin polymerisation and p38 MAP kinase. Thromb Haemost 2011;105:461-72.
14. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009;73:361-70.
15. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol 2008;75:405-13.
16. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-64.
17. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:58-63.
18. Nishida M, Carley WW, Gerritsen ME, Ellingsen O, Kelly RA, Smith TW. Isolation and characterization of human and rat cardiac microvascular endothelial cells. Am J Physiol 1993;264(2 Pt 2):H639-52.
19. Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 2000;165:2712-8.
20. Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/ protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2007;292:H1937-42.
21. Martínez-Sales V, Vila V, Ferrando M, Reganon E. Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate. Cytotechnology 2011;63:1-5.
22. Lee KM, Lee HJ, Kim MK, Kim HS, Jung GS, Hur SH, Kim HT, Cho WH, Kim JG, Kim BW, Lim JO, Choi HS, Lee KU, Park KG, Lee IK. Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. Atherosclerosis 2009;207:391-8.
23. Nakayama N, Nakamura T, Okada H, Iwaki S, Sobel BE, Fujii S. Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-b. Coron Artery Dis 2011;22:468-78.
24. Velusamy T, Jain SK. Effects of high glucose and ketosis (acetoacetate, ss-hydroxybutyrate) on PAI-1 secretion in human umbilical vascular endothelial cells. Clin Appl Thromb Hemost 2011;17:288-92.
25. Iwasaki H, Okamoto R, Kato S, Konishi K, Mizutani H, Yamada N, Isaka N, Nakano T, Ito M. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 2008;196:22-8.
26. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005;111:3261-8.
27. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, Trikas A, Pitsavos C, Stefanadis C. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005;91:27-31.
28. Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, Zhao R, Fenton JW 2nd, Ofosu FA, Velthuis HT, van Mierlo G, Shen GX. Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus 1. Diabetes Res Clin Pract 2005;70:110-8.
29. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002;135:284-92.
30. Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis 2008;196:565-73.
31. Jeong IK, Oh DH, Park SJ, Kang JH, Kim S, Lee MS, Kim MJ, Hwang YC, Ahn KJ, Chung HY, Chae MK, Yoo HJ. Inhibition of NF-kB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med 2011;43:684-92.
32. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007;50:17-24.
33. Kunieda Y, Nakagawa K, Nishimura H, Kato H, Ukimura N, Yano S, Kawano H, Kimura S, Nakagawa M, Tsuji H. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 2003;110:227-34.
34. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
35. He F, Peng J, Deng XL, Yang LF, Wu LW, Zhang CL, Yin F. RhoA and NF-kB are involved in lipopolysaccharide-induced brain microvascular cell line hyperpermeability. Neuroscience 2011;188:35-47.
36. He Y, Xu H, Liang L, Zhan Z, Yang X, Yu X, Ye Y, Sun L. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 2008;58:3366-76.
37. Cirillo P, Pacileo M, De Rosa S, Calabro P, Gargiulo A, Angri V, Prevete N, Fiorentino I, Ucci G, Sasso L, Petrillo G, Musto D'Amore S, Chiariello M. HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells. J Vasc Res 2007;44:460-70.
38. Maeda A, Yano T, Itoh Y, Kakumori M, Kubota T, Egashira N, Oishi R. Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis 2010;208:112-8.
39. Rattan R, Giri S, Singh AK, Singh I. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radic Biol Med 2003;35:1037-50.
40. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008;74:476-84.